Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
Phio Pharmaceuticals Corp. (PHIO)
Last phio pharmaceuticals corp. earnings: 11/12 07:45 am
Check Earnings Report
Company Research
Source: GlobeNewswire
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update. Recent Corporate Updates Phio’s INTASYL compound PH-762 is currently being investigated in an open-label Phase 1b clinical study (NCT 06014086) to evaluate the safety and tolerability of intratumoral PH-762 in cutaneous squamous cell (cSCC), melanoma, or Merkel cell carcinoma. Two patients have already completed treatment. Four sites across the US are now engaged in the Phase 1b study. The sites are: George Washington University in Washington DCBanner MD Anderson in ArizonaCentricity Research in OhioI
Show less
Read more
Impact Snapshot
Event Time:
PHIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHIO alerts
High impacting Phio Pharmaceuticals Corp. news events
Weekly update
A roundup of the hottest topics
PHIO
News
- Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging [Yahoo! Finance]Yahoo! Finance
- Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 [Yahoo! Finance]Yahoo! Finance
- Phio Pharmaceuticals Secures New Investor [Yahoo! Finance]Yahoo! Finance
- Phio Pharmaceuticals Secures New InvestorGlobeNewswire
- Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) [Yahoo! Finance]Yahoo! Finance
PHIO
Analyst Actions
- 5/14/24 - HC Wainwright
PHIO
Sec Filings
- 6/21/24 - Form 8-K
- 6/11/24 - Form 4
- 6/10/24 - Form 4
- PHIO's page on the SEC website